A Positron Emission Tomography scan is a very useful imaging test that can assist in terms of revealing the biochemical or metabolic function of the body tissues and organs. The PET scan primarily uses a radioactive drug (tracer) to showcase both abnormal and normal metabolic activities. A PET scan can often identify the abnormal metabolism of the tracer in a wide range of diseases before the disease exactly shows up on other imaging tests, like magnetic resonance imaging (MRI) and computerized tomography (CT). The tracer is mostly injected into a vein within the arm or hand. The tracer will then accumulate in key areas of the body that have greater levels of biochemical or metabolic activities, which often pinpoints the exact location of the disease. The PET images are mostly combined with MRI or CT and hence are called PET-CT or PET-MRI scans.
The Market for Global Positron Emission Tomography is anticipated to reach a landmark of USD 1508.57 Mn by 2030 from USD 1016.20 Mn in 2020, growing at an overall CAGR of 4.03 percent during the forecasted period. The high success rate that is associated with the technology of Positron Emission Tomography has enabled the patients to opt for this crucial technology, thereby resulting in the overall growth of this market. In accordance with the Cancer imaging journal, positron emission tomography is 97 percent to 100 percent successful in terms of identifying recurrent tumours. Also, the PET imaging devices market is increasing due to its wide range of uses and applications. The PET imaging devices are primarily used to identify the various brain problems and disorders related to head, lung, cervical, breast, neck, colorectal, oesophageal, skin, and many others. Moreover, the PET can also be utilized in the overall treatment of cancer and the detection of key diseases like Parkinson’s disease, heart disease, epilepsy, Huntington’s disease and cerebrovascular diseases. In accordance with the Centre for Neurological Treatment and Research, In the United States, one in every 10,000 people has Huntington’s Disease.
Recent Developments regarding the Positron Emission Tomography Market
- In the month of January 2022, GE Healthcare received an additional FDA 510 (k) clearance for its remarkable technology of SIGNA PET/MRI, which could assist the clinicians in terms of achieving more and enhanced scanning. It will also make them to provide more effective treatment paths for their patients, especially in the fields like neurology, cardiology, oncology, and many others.
- In the month of January 2022, Positron Corporation had declared its strategic tie-up with Neusoft Medical Systems in order to manufacture, distribute and improvise its research and development of Positron’s new PET-CT device. Positron Corporation believes that this tie-up will allow them to further enhance its PET-CT technology while advancing into the oncology segment.
- In March 2021, Siemens Healthineers announced the FDA Clearance on its Biograph Vision Quadra PET-CT Scanner, which is mainly built for translational as well as clinical use, thereby improvising the healthcare outcomes. Siemens feels that this introduction of this device would assist the clinicians in better identification of the diseases.